SREBF1 and metabolic dysfunction-associated steatotic liver disease: In T2DM, insulin resistance can abnormally activate SREBP-1c, leading to excessive accumulation of FFAs and TGs, which results in the overproduction of ROS and subsequently activates inflammatory signaling pathways, releasing large amounts of inflammatory cytokines and contributing to the onset and progression of NAFLD (10, 11).